Teva Plans to Sue Dr. Reddy's Over Copaxone Patent Infringement

Aug 12, 2014

Teva Pharmaceutical Industries Ltd. confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE 40 mg/mL product from Dr. Reddy’s Laboratories Inc.

According to a press release, Teva said it will continue to vigorously defend its COPAXONE intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45-day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30-month stay of FDA approval of Dr. Reddy’s ANDA.

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments